Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: BridgeBio Pharma Inc., 3 years.
BridgeBio Pharma Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BridgeBio Pharma Inc. June 21, 202496.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 9, 2026 | BridgeBio Pharma Inc. | Option exercise | +17,167 | $16.75 | $287,547 |
| Jul 9, 2026 | BridgeBio Pharma Inc. | Open-market sale | −17,167 | $84.00 | $1,442,028 |
| Jun 22, 2026 | BridgeBio Pharma Inc. | Grant or award | +3,990 | — | — |
| Mar 4, 2026 | BridgeBio Pharma Inc. | Option exercise | +64,921 | $8.45 | $548,582 |
| Mar 4, 2026 | BridgeBio Pharma Inc. | Open-market sale | −64,921 | $64.87 | $4,211,425 |
| Aug 5, 2025 | BridgeBio Pharma Inc. | Option exercise | +17,167 | $16.75 | $287,547 |
| Aug 5, 2025 | BridgeBio Pharma Inc. | Open-market sale | −17,167 | $49.00 | $841,183 |
| Jun 20, 2025 | BridgeBio Pharma Inc. | Grant or award | +6,589 | — | — |
| Apr 14, 2025 | BridgeBio Pharma Inc. | Option exercise | +10,000 | $8.45 | $84,500 |
| Apr 14, 2025 | BridgeBio Pharma Inc. | Open-market sale | −10,000 | $35.00 | $350,000 |
| Apr 1, 2025 | BridgeBio Pharma Inc. | Option exercise | +30,000 | $8.45 | $253,500 |
| Apr 1, 2025 | BridgeBio Pharma Inc. | Open-market sale | −30,000 | $34.05 | $1,021,500 |
Questions about Andrea Ellis
What boards is Andrea Ellis on?
Andrea Ellis sits on the board of BridgeBio Pharma Inc.
How long has Andrea Ellis served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.